EOT was the data they stopped taking the drug . Then there was a 2 wk follow up to see if there was any lingering benefit ....which they recorded for the 200 mg dose . The problem is that they say there was probably full cell penetration at the 200 mg dose so there was no benefit from a larger dose ...however ...if there was full cell penetration at the 200 dose ...and the 400 dose ...those graphs should be the same or close . But they aren't
RMB. In the CC the Co thought the difference between the 400 mg and 200 mg dose was that there were more with advanced DME in the 200 mg dose . So those with limited DME ...more of them in the 400 mg cohort ...saw limited benefit as not a lot to improve on.
So the challenge is to recruit those with moderate DME who aren't yet taking the eye injections